We use cookies to analyze site usage and improve your experience. You can accept all, reject non-essential, or customize. See our Privacy Policy.
For women who cannot or prefer not to use hormone therapy, evidence-based non-hormonal treatments including paroxetine and desvenlafaxine are available — targeting vasomotor symptoms and mood disruption without estrogen. Available to women across Arizona's hot desert climate — entirely online.
Start Your Free Intake →Licensed in Arizona · FDA-registered pharmacy · Reviewed within 24 hours · Ships free
Connect with a kindr-licensed provider who can evaluate whether Non-Hormonal Menopause Treatment is appropriate for your health history and symptoms — from anywhere in Arizona.
Non-hormonal menopause treatments are prescription medications that reduce vasomotor symptoms (hot flashes, night sweats) and, in many cases, associated mood and sleep disruption — without altering estrogen or progesterone levels. The category includes select SSRIs and SNRIs (paroxetine, desvenlafaxine, escitalopram, venlafaxine), gabapentin, and the newer neurokinin-3 receptor antagonist fezolinetant.
These medications are the standard of care for women with a history of hormone-sensitive cancer, personal or strong family history of venous thromboembolism, or other conditions where estrogen is contraindicated — and for women who simply prefer a non-hormonal approach.
SSRIs and SNRIs modulate serotonin and norepinephrine signaling in the hypothalamic thermoregulatory center, reducing the exaggerated heat-loss response that produces hot flashes. Gabapentin acts through calcium channel modulation and is especially useful for nighttime symptoms. Fezolinetant blocks neurokinin-3 receptors on hypothalamic KNDy neurons, directly reducing the neurologic driver of vasomotor symptoms discovered in recent decade of menopause research.
Paroxetine (7.5 mg) is the only FDA-approved non-hormonal medication specifically labeled for vasomotor symptoms of menopause, based on two randomized controlled trials showing significant reduction in hot flash frequency and severity. Fezolinetant (Veozah), FDA-approved in 2023, showed 55-65% reduction in moderate-to-severe hot flashes at 12 weeks in the SKYLIGHT trials — comparable to hormone therapy.
NAMS 2023 non-hormonal position statement identifies fezolinetant, paroxetine, desvenlafaxine, escitalopram, gabapentin, and oxybutynin as evidence-based options for vasomotor symptoms in women who cannot or choose not to use hormone therapy.
Most side effects are mild and settle within the first 4-8 weeks. Report anything severe or persistent to your prescriber.
Medically reviewed by the kindr Clinical Team. Content reflects the 2022 NAMS Position Statement and current Endocrine Society guidelines. Last reviewed 2026.
Complete your intake online from anywhere in Arizona
A licensed Arizona provider reviews within 24 hours
If prescribed, ships free to your door
A kindr physician reviews your health history and reasons for avoiding HRT. Non-hormonal prescription alternatives are evaluated and prescribed where clinically appropriate — shipped monthly.
In 2025, the FDA updated its guidance on hormone therapy for menopause, removing longstanding warnings that had deterred many women from effective treatment. Speak with a kindr provider about what this means for you.
Connect with a board-certified kindr physician licensed to practice in Arizona. No waiting rooms. No referrals. Reviewed within 24 hours.
Start Your Free Intake →Non-Hormonal Menopause Treatment is a prescription medication. A licensed provider must evaluate whether this treatment is right for you. kindr is not a pharmacy. Medications are prescribed by licensed independent physicians and fulfilled by FDA-registered 503A compounding pharmacies. kindr does not guarantee any specific treatment will be prescribed.